MPS PHARMAA LIMITED
BBSE:ADVIKLA2.08
INR
0.00
(0.00%)
ISIN
INE537C01019
Return %
Stock
S&P 500
1Y
0.48
14.20
3Y
-21.80
81.12
5Y
71.90
68.34
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.Company Description
- CEO
- Peeyush Kumar Aggarwal
- Full Time Employees
- 18
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- New Delhi India
- IPO Date
- Feb 28, 1996
- Website
- mpspharmaa.com
- Similar Companies
- Business
- MPS Pharmaa Limited (formerly known as Advik Laboratories Limited) is an India-based pharmaceutical company engaged in the research, development, manufacturing, marketing, and distribution of generic pharmaceutical formulations, healthcare products, and therapeutic solutions. Founded in 1994 and headquartered in New Delhi, India, with manufacturing facilities located in Sohna, Haryana, the company serves both domestic and international markets, catering to institutional buyers, government health agencies, hospitals, pharmacy chains, and independent healthcare distributors across Asia, Africa, the CIS region, and Latin America. The company operates primarily within the formulation manufacturing sector, offering an extensive portfolio of prescription medicines and over-the-counter products across diverse dosage forms and therapeutic areas, including: oral solid formulations comprising immediate-release, sustained-release, enteric-coated, and dispersible tablets; hard gelatin and soft gelatin capsules; oral liquid formulations including pediatric suspensions, therapeutic syrups, and oral drops; sterile parenteral preparations including liquid injectables and dry powder injectables packaged in ampoules and vials; topical formulations including dermatological creams, therapeutic ointments, and gels; ophthalmic and otic formulations including sterile eye and ear drops; and specialized beta-lactam and non-beta-lactam antibiotics. Its product portfolio spans core therapeutic categories such as: antimicrobial and antibacterial medications; analgesics, antipyretics, and anti-inflammatory drugs; cardiovascular and anti-hypertensive agents; gastrointestinal and anti-ulcer medications; anti-diabetic formulations; central nervous system agents; respiratory and anti-allergic treatments; and dietary supplements, multivitamins, and mineral complexes. In addition to manufacturing its proprietary brands, the company offers third-party contract manufacturing, loan licensing, custom formulation development, and private-label packaging services for domestic and global pharmaceutical enterprises. In recent developments, the company executed a major corporate rebranding and reorganization, officially changing its name from Advik Laboratories Limited to MPS Pharmaa Limited to reflect a renewed strategic direction and broader global market focus. To fund ongoing business growth and working capital requirements, the company approved capital mobilization initiatives through the preferential allotment of equity shares and convertible warrants. On the operational front, MPS Pharmaa Limited has undertaken infrastructure modernization and capacity enhancement projects at its manufacturing facility to adhere to revised Schedule M and World Health Organization Good Manufacturing Practice (WHO-GMP) compliance standards. Furthermore, the company has expanded its commercial portfolio into high-demand nutraceuticals and preventive healthcare products, broadened its participation in institutional and governmental healthcare tenders, and entered into new international distribution partnerships to accelerate export growth.